Literature DB >> 24709420

Strain background determines lymphoma incidence in Atm knockout mice.

Paula C Genik1, Helle Bielefeldt-Ohmann2, Xianan Liu3, Michael D Story4, Lianghao Ding4, Jamie M Bush5, Christina M Fallgren1, Michael M Weil6.   

Abstract

About 10% to 30% of patients with ataxia-telangiectasia (A-T) develop leukemias or lymphomas. There is considerable interpatient variation in the age of onset and leukemia/lymphoma type. The incomplete penetrance and variable age of onset may be attributable to several factors. These include competing mortality from other A-T-associated pathologies, particularly neurodegeneration and interstitial lung disease, allele-specific effects of ataxia-telangiectasia mutated (ATM) gene mutations. There is also limited evidence from clinical observations and studies using Atm knockout mice that modifier genes may account for some variation in leukemia/lymphoma susceptibility. We have introgressed the Atm(tm1Awb) knockout allele (Atm(-)) onto several inbred murine strains and observed differences in thymic lymphoma incidence and latency between Atm(-/-) mice on the different strain backgrounds and between their F1 hybrids. The lymphomas that arose in these mice had a pattern of sequence gains and losses that were similar to those previously described by others. These results provide further evidence for the existence of modifier genes controlling lymphomagenesis in individuals carrying defective copies of Atm, at least in mice, the characterized Atm(-) congenic strain set provides a resource with which to identify these genes. In addition, we found that fewer than expected Atm(-/-) pups were weaned on two strain backgrounds and that there was no correlation between body weight of young Atm-/- mice and lymphoma incidence or latency.
Copyright © 2014 Neoplasia Press, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24709420      PMCID: PMC3978393          DOI: 10.1593/neo.131980

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  30 in total

1.  Variations in Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis.

Authors:  N Mori; Y Matsumoto; M Okumoto; N Suzuki; J Yamate
Journal:  Oncogene       Date:  2001-06-21       Impact factor: 9.867

2.  Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis.

Authors:  K E Gurley; C J Kemp
Journal:  Curr Biol       Date:  2001-02-06       Impact factor: 10.834

3.  Association of ataxia telangiectasia mutated (ATM) gene mutation/deletion with rhabdomyosarcoma.

Authors:  Peilin Zhang; Kunjan S Bhakta; Pier Lorenzo Puri; Robert O Newbury; James R Feramisco; Jean Y Wang
Journal:  Cancer Biol Ther       Date:  2003 Jan-Feb       Impact factor: 4.742

4.  Atm knock-in mice harboring an in-frame deletion corresponding to the human ATM 7636del9 common mutation exhibit a variant phenotype.

Authors:  K Spring; S Cross; C Li; D Watters; L Ben-Senior; P Waring; F Ahangari; S L Lu; P Chen; I Misko; C Paterson; G Kay; N I Smorodinsky; Y Shiloh; M F Lavin
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

Review 5.  Cancer in ataxia-telangiectasia patients.

Authors:  F Hecht; B K Hecht
Journal:  Cancer Genet Cytogenet       Date:  1990-05

6.  Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene.

Authors:  Y Yu; R Okayasu; M M Weil; A Silver; M McCarthy; R Zabriskie; S Long; R Cox; R L Ullrich
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

Review 7.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

8.  Atm-deficient mice: a paradigm of ataxia telangiectasia.

Authors:  C Barlow; S Hirotsune; R Paylor; M Liyanage; M Eckhaus; F Collins; Y Shiloh; J N Crawley; T Ried; D Tagle; A Wynshaw-Boris
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

9.  Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by Friend murine leukemia virus.

Authors:  Y Ben-David; E B Giddens; A Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

10.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

View more
  12 in total

1.  A novel mouse model for ataxia-telangiectasia with a N-terminal mutation displays a behavioral defect and a low incidence of lymphoma but no increased oxidative burden.

Authors:  Andrew Campbell; Brittany Krupp; Jared Bushman; Mark Noble; Christoph Pröschel; Margot Mayer-Pröschel
Journal:  Hum Mol Genet       Date:  2015-08-26       Impact factor: 6.150

2.  Mutation of ataxia-telangiectasia mutated is associated with dysfunctional glutathione homeostasis in cerebellar astroglia.

Authors:  Andrew Campbell; Jared Bushman; Joshua Munger; Mark Noble; Christoph Pröschel; Margot Mayer-Pröschel
Journal:  Glia       Date:  2015-10-15       Impact factor: 7.452

3.  Nbn-Mre11 interaction is required for tumor suppression and genomic integrity.

Authors:  Jun Hyun Kim; Alexander V Penson; Barry S Taylor; John H J Petrini
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-08       Impact factor: 11.205

4.  Ataxia-telangiectasia mutated is required for the development of protective immune memory after influenza A virus infection.

Authors:  Rachel Warren; William Domm; Min Yee; Andrew Campbell; Jane Malone; Terry Wright; Margot Mayer-Pröschel; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-11       Impact factor: 5.464

5.  A novel, ataxic mouse model of ataxia telangiectasia caused by a clinically relevant nonsense mutation.

Authors:  Harvey Perez; May F Abdallah; Jose I Chavira; Angelina S Norris; Martin T Egeland; Karen L Vo; Callan L Buechsenschuetz; Valentina Sanghez; Jeannie L Kim; Molly Pind; Kotoka Nakamura; Geoffrey G Hicks; Richard A Gatti; Joaquin Madrenas; Michelina Iacovino; Peter J McKinnon; Paul J Mathews
Journal:  Elife       Date:  2021-11-01       Impact factor: 8.713

6.  Mouse Tumor Biology (MTB): a database of mouse models for human cancer.

Authors:  Carol J Bult; Debra M Krupke; Dale A Begley; Joel E Richardson; Steven B Neuhauser; John P Sundberg; Janan T Eppig
Journal:  Nucleic Acids Res       Date:  2014-10-20       Impact factor: 16.971

7.  The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment.

Authors:  Jianmin Chen; Yanping Chen; Graham Vail; Heiman Chow; Yang Zhang; Lauren Louie; Jiali Li; Ronald P Hart; Mark R Plummer; Karl Herrup
Journal:  Mol Neurodegener       Date:  2016-08-18       Impact factor: 14.195

Review 8.  Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.

Authors:  Lin Mei; Junran Zhang; Kai He; Jingsong Zhang
Journal:  J Hematol Oncol       Date:  2019-04-24       Impact factor: 17.388

9.  NAD+ supplementation prevents STING-induced senescence in ataxia telangiectasia by improving mitophagy.

Authors:  Beimeng Yang; Xiuli Dan; Yujun Hou; Jong-Hyuk Lee; Noah Wechter; Sudarshan Krishnamurthy; Risako Kimura; Mansi Babbar; Tyler Demarest; Ross McDevitt; Shiliang Zhang; Yongqing Zhang; Mark P Mattson; Deborah L Croteau; Vilhelm A Bohr
Journal:  Aging Cell       Date:  2021-03-18       Impact factor: 9.304

10.  Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease.

Authors:  Jennifer Q J Zhang; Sayanthooran Saravanabavan; Gopala K Rangan
Journal:  Cells       Date:  2021-03-03       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.